Management of castration-resistant, taxane-resistant prostate cancer

Tomasz M. Beer

Research output: Contribution to journalArticlepeer-review


Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalONCOLOGY (United States)
Issue number8
StatePublished - Aug 15 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Management of castration-resistant, taxane-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this